GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Total Liabilities

Cleo Diagnostics (ASX:COV) Total Liabilities : A$0.20 Mil (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Total Liabilities?

Cleo Diagnostics's Total Liabilities for the quarter that ended in Dec. 2023 was A$0.20 Mil.

Cleo Diagnostics's quarterly Total Liabilities increased from Dec. 2022 (A$1.63 Mil) to Jun. 2023 (A$2.02 Mil) but then declined from Jun. 2023 (A$2.02 Mil) to Dec. 2023 (A$0.20 Mil).

Cleo Diagnostics's annual Total Liabilities stayed the same from . 20 (A$0.00 Mil) to . 20 (A$0.00 Mil) but then increased from . 20 (A$0.00 Mil) to Jun. 2023 (A$2.02 Mil).


Cleo Diagnostics Total Liabilities Historical Data

The historical data trend for Cleo Diagnostics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Total Liabilities Chart

Cleo Diagnostics Annual Data
Trend Jun23
Total Liabilities
2.02

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23
Total Liabilities 1.63 2.02 0.20

Cleo Diagnostics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cleo Diagnostics's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.02+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=2.02

Total Liabilities=Total Assets (A: Jun. 2023 )-Total Equity (A: Jun. 2023 )
=1.077--0.943
=2.02

Cleo Diagnostics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.199+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=0.20

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=10.739-10.54
=0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cleo Diagnostics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Cleo Diagnostics (ASX:COV) Business Description

Traded in Other Exchanges
N/A
Address
480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines